KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

About KEYTRUDA® (pembrolizumab) injection, 100 mg KEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help detect and ...

Health minister hopes a key injectable cancer drug will be available in all five trusts "as soon as possible".

Keytruda, a Merck cancer immunotherapy that has become the world’s top-selling medication, is administered as an intravenous infusion over the course of 30 minutes. The pharmaceutical giant now has ...

The U.S. Food and Drug Administration (FDA) has approved a new way to give pembrolizumab (brand name: Keytruda), one of the most widely used immunotherapy treatments for cancer. For the first time, ...

EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...

A new injectable form of a key cancer drug could see thousands of NHS patients across the UK spending far less time in hospital. Keytruda, which is already used to treat multiple cancers, is a type of ...

The NHS is introducing a one-minute jab that could help tens of thousands of cancer patients.

Patients in East Yorkshire and North Lincolnshire are set to benefit from quicker treatment.

The NHS is rolling out a one-minute immunotherapy injection for over a dozen types of cancer, including lung, breast, and cervical cancer. This new injectable form of pembrolizumab (Keytruda) can ...

The Department of Health says it is "aware" of the jab and is "exploring" how it can be made available "as soon as possible".

Positive opinion granted for SC administration of KEYTRUDA for all adult indications approved in the European Union for KEYTRUDA Positive opinion also granted for KEYTRUDA as part of a perioperative ...